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Abstract
Introduction: The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer prevention
is still under debate. The FDA recently concluded that the increased prevalence of high-grade tumors among 5-ARI-treated
patients must not be neglected, and they decided to disallow the use of 5-ARIs for prostate cancer prevention. This study
was conducted to verify the effects of finasteride on prostate cell migration and invasion and the related enzymes/proteins
in normal human and tumoral prostatic cell lines.
Materials and Methods: RWPE-1, LNCaP, PC3 and DU145 cells were cultivated to 60% confluence and exposed for different
periods to either 10 mM or 50 mM finasteride that was diluted in culture medium. The conditioned media were collected and
concentrated, and MMP2 and MMP9 activities and TIMP-1 and TIMP-2 protein expression were determined. Cell viability,
migration and invasion were analyzed, and the remaining cell extracts were submitted to androgen receptor (AR) detection
by western blotting techniques. Experiments were carried out in triplicate.
Results: Cell viability was not significantly affected by finasteride exposure. Finasteride significantly downregulated MMP2
and MMP9 activities in RWPE-1 and PC3 cells and MMP2 in DU145 cells. TIMP-2 expression in RWPE-1 cells was upregulated
after exposure. The cell invasion of all four tested cell lines was inhibited by exposure to 50 mM of finasteride, and migration
inhibition only occurred for RWPE-1 and LNCaP cells. AR was expressed by LNCaP, RWPE-1 and PC3 cells.
Conclusions: Although the debate on the higher incidence of high-grade prostate cancer among 5-ARI-treated patients
remains, our findings indicate that finasteride may attenuate tumor aggressiveness and invasion, which could vary
depending on the androgen responsiveness of a patient’s prostate cells.
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Introduction
Prostate cancer is the most common malignancy in men and
accounts for $8 billion and an average cost of $81658 per patient,
from diagnosis to death, in the USA [1]. A number of agents are
currently being investigated for the prevention of prostate cancer
[2]. Finasteride, a type 2 5-alpha reductase inhibitor (5-ARI) that
blocks the conversion of testosterone (T) into dihydrotestosterone
(DHT) [3], is a well-known drug that is used for the treatment of
benign prostatic hyperplasia [4] and has been suggested to act as a
chemopreventive agent for prostate cancer. The Prostate Cancer
Prevention Trial (PCPT) demonstrated a 24.8% reduction in
overall and low-grade prostate cancer risk with the administration
of finasteride. However, high-grade cancers were noted in 6.4% of
finasteride-treated patients, compared to 5.1% of men who
received a placebo [5,6]. This finding led to an important
question: did finasteride induce high-grade cancer or increase its
detection? This question was followed by an intense debate about
factual or artifactual overestimation of high-grade cases in the
finasteride-treated patients [3,7], which divided urologists and
prostate researchers. More recently, the REDUCE trial reported
similar outcomes after 5-ARI dutasteride treatment. Recognizing
the importance of this issue, the Food and Drug Administration
(FDA) has recently reanalyzed the data from the PCPT and
REDUCE trials and concluded that finasteride and dutasteride
treatments might increase the risk of a more serious form of
prostate cancer. Therefore, they decided to disallow the use of
these agents for prostate cancer prevention [8]. In addition, a
recently published experimental study revealed similar outcomes
to the PCPT and REDUCE trials [9]. The authors demonstrated
that the incidence of poorly differentiated carcinoma was
increased in C57BL/6 TRAMP6FVB mice fed with a finasteride
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supplemented diet, and considered this as an adverse effect of
finasteride treatment, rather than an artifactual effect [9].
High-grade prostate cancer cases, such as those observed in the
5-ARI-treated patients, are commonly associated with an
increased expression of matrix metalloproteinases (MMPs), a
family of zinc and calcium dependent endopeptidases that are
responsible for extracellular matrix (ECM) remodeling, which
contributes to invasive and metastatic phenotypes of prostate
cancer cells [10–13], and decreased expression of tissue inhibitor
of matrix metalloproteinases (TIMPs) [13], a class of naturally
occurring inhibitors of MMPs that tightly regulate their activity
and are expressed in a variety of cell types [11].
Because ECM degradation is known to be a major step during
cancer progression [10,12,13], our group has been investigating
the effects of finasteride upon MMP and TIMP modulation in an
attempt to explain why finasteride-treated patients had higher-
grade prostate cancers. We previously demonstrated that finaste-
ride treatment increased the expression of MMP9 and decreased
the expression of MMP2 in the rat ventral prostate [14,15] and
that it downregulated the mRNA levels of TIMP-1 and TIMP-2 in
the rat ventral prostate [15]. Moreover, we have recently
demonstrated that finasteride also reduces the MMP2 gelatinolytic
activity in a variety of human prostate cell lines [16]. We
conducted the present study to ascertain whether finasteride
treatment interferes with the migration and invasive potential of
the normal human prostate cell line RWPE-1 and the tumoral
epithelial cell lines LNCaP, PC3 and DU145, which have different
androgen receptor (AR) profiles.
Materials and Methods
Cell Cultures
One vial each of the RWPE-1 (non-tumoral, wild type AR+),
LNCaP (tumoral, mutated AR+) and PC3 (tumoral, AR2) cell lines
were acquired from the American Type Culture Collection
(ATCCTM). DU145 (tumoral, AR2) cells were kindly donated
by Dr. Heloisa Sobreiro Selistre de Arau´jo from the Department
of Physiology – UFSCar, Brazil (originally acquired from the
ATCCTM). Although not isogenic, these cell lines were selected to
be representative of 3 distinct in vivo finasteride exposure
situations: a patient with a normal prostate (represented in vitro
by the RWPE-1 cell line), a patient with androgen-sensitive
prostate cancer (represented in vitro by the LNCaP cell line) and a
patient with castration-resistant prostate cancer (represented
in vitro by the PC3 and DU145 cell lines). The experiments were
performed two months after the acquisition of the cell lines. The
RWPE-1 cells were cultivated using Keratinocyte Serum Free
Medium (InvitrogenTM) supplemented with 0.05 mg/ml bovine
pituitary extract, 5 ng/ml recombinant human epidermal growth
factor (EGF) and 1% antibiotic/antimycotic solution (Invitro-
genTM). The LNCaP, PC3 and DU145 cells were cultivated using
RPMI medium (InvitrogenTM) supplemented with 10% fetal
bovine serum (SFB) (InvitrogenTM) and 1% antibiotic/antimycotic
solution (InvitrogenTM). All cell culture procedures were per-
formed under strict sterile conditions and kept inside a 5% CO2
incubator (Thermo ScientificTM). The initial vial of each cell line
was expanded up to 10 vials and individually cryopreserved in the
respective cell culture medium supplemented with 20% FBS and
10% dimethylsulfoxide (DMSO) (Sigma-AldrichTM) to constitute
the cell bank.
Finasteride Exposure and Cell Viability
All cell lines were then thawed and individually seeded at 26104
cells/cm2 in 6-well culture plates (TPPTM). Experiments were
carried out in triplicate. Finasteride concentrations were chosen
based on a previous study, in which 10 mM and 50 mM induced
significant metabolic modulation upon prostate tumoral cells [17].
Upon reaching 60% confluence, the cells were washed three times
with sterile D-PBS (GIBCO/InvitrogenTM), and the recommend-
ed culture medium (FBS free) was added as follows: 1) control
treatment - supplemented with 0.1% DMSO; 2) low-dose
finasteride treatment - supplemented with 0.1% DMSO plus
10 mM finasteride (SigmaTM); and 3) high-dose finasteride
treatment - supplemented with 0.1% DMSO plus 50 mM
finasteride (SigmaTM). Finasteride was diluted in DMSO, and
the DMSO/finasteride solution was diluted in culture medium.
During all finasteride exposure treatments, the cells were observed
under a phase-contrast inverted microscope (ZeissTM) for general
morphology and bacterial and fungal contamination. After 24, 48
and 72 hours of exposure, the conditioned medium (CM) was
collected and individually stored at 280uC. The remaining
attached cells were individually retrieved by trypsin digestion,
and an aliquot was assessed for viability by Trypan Blue staining.
The remaining cells were individually centrifuged at 1200 RPM
for 10 minutes to obtain a cell pellet to produce protein extracts.
FBS was removed during finasteride exposure because it is known
to contain high levels of MMPs, which would interfere with the
subsequent gelatinolytic assays.
Conditioned Medium and Cell Extract Processing
The CM was concentrated 10X using CentriprepH 10,000
MWCO (MilliporeTM) tubes by centrifugation at 4900 RPM for
30 minutes. The respective cell pellets were submitted to protein
extraction using an in-house-produced 50 mM Tris-HCl, 0.2 M
NaCl, 10 mM CaCl2, 0.1% Triton X-100 protein extraction
buffer supplemented with 1% protease inhibitor cocktail (Sigma-
AldrichTM) to obtain cell extracts. The protein extraction buffer
was chosen after comparison with a commercially available buffer
(RIPA Buffer, Thermo ScientificTM), which revealed better-
preserved MMP gelatinolytic activity by zymography (data not
shown). Protein extraction was conducted by repetitive pipetting
and vortexing, followed by 1 hour of rest on ice and a final
centrifugation at 5000 RPM for 20 minutes at 4uC. Finally, the
CM and protein extracts were submitted to protein quantification
using a NanoDrop 2000 (Thermo ScientificTM) spectrophotometer
and the Protein A280/260 protocol. It is important to emphasize
that the CM was FBS free; therefore, all proteins in the CM were
produced by the cells.
MMP2 and MMP9 Activity Assays
The total (pro-form+active form) MMP2 and MMP9 activities
in the CM and cell extracts were measured using the BiotrakH
Activity Assays (GE Healthcare LifeSciencesTM) according to the
manufacturer’s guidelines. Briefly, equal amounts (100 mg) of
pooled CM or cell extract (per triplicate treatment) were pipetted
into a 96-well microplate coated with anti-human-MMP2 or anti-
human-MMP9 antibodies. Standards of human recombinant pro-
MM2 or pro-MMP9 were pipetted into the respective wells, with
values ranging from 0.19 to 3 ng/ml (for MMP2) and 0.125 to
4 ng/ml (for MMP9) as instructed by the manufacturer. After an
overnight incubation at 4uC and washing, 50 mL of a 0.5 mM p-
aminophenylmercuric acetate (APMA) solution was pipetted into
all wells to activate the pro-forms of MMP2 and MMP9.
Subsequently, 50 mL of a detection reagent (modified urokinas-
e+S-2444TM peptide substrate) was added to all wells. The plates
were incubated at 37uC for 6 (for MMP2) or 2 hours (for MMP9),
and the integrated optical density (IOD) was measured at 405 nm
using a spectrophotometric plate reader. Finally, a fold-change
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graphic was made by dividing the obtained IODs from the treated
CM/extracts by their respective control values. Alternatively, the
MMP2 and MMP9 activities were assessed using standard gelatin
zymography, as previously described [16].
TIMP-1 and TIMP-2 Protein Quantification
The TIMP-1 and TIMP-2 protein levels in the CM were
measured using solid-phase ELISA BiotrakH Human Assays (GE
Healthcare LifeSciencesTM) according to the manufacturer’s
guidelines. Briefly, equal amounts (100 mg) of pooled CM (per
triplicate treatment) were pipetted into a 96-well microplate coated
with anti-human-TIMP-1 or anti-human-TIMP-2 antibodies.
Standards of human recombinant TIMP-1 or TIMP-2 were
pipetted into the respective plate wells, with values ranging from
3.13 to 50 ng/ml (for TIMP-1) and 8 to 128 ng/ml (for TIMP-2).
After a 2 hour incubation at 25uC and washing, 100 mL of a
peroxidase conjugate solution was pipetted into all wells, and the
plates were further incubated for 2 hours at 25uC. Subsequently,
100 mL of a tetramethylbenzidine (TMB)/hydrogen peroxide
solution was added to all wells. The plates were incubated at
room temperature for 30 minutes, and the IOD was measured at a
630 nm using a spectrophotometric plate reader. Finally, a fold-
change graphic was made by dividing the obtained IODs from the
treated treatments by their respective control values.
Migration Assay
The migration potential of all cell lines was investigated using
the BD BioCoatTM Migration Insert (BD BiosciencesTM). The
porous membrane (8 mm pore size) was hydrated with 500 ml of
serum-free bicarbonate-based medium for 2 hours. After hydra-
tion, 500 ml of RPMI 1640 medium with 5% FBS (for LNCaP,
PC3 and DU145 cells) or 500 ml of keratinocyte medium with 5%
FBS (for RWPE-1 cells) was added to the lower chamber of the 24-
well plate. These prostate cell lines were previously cultivated in
50 mM finasteride medium or control medium for 72 hours,
harvested and individually cultivated in 200 ml serum-free medium
(with or without 50 mM finasteride) in the insert at a density of
16105 total cells. The plates were incubated with 5% CO2 at 37uC
for 22 hours according to the manufacturer’s guidelines. The cells
that did not migrate, which were located on the top of the insert
membrane, were scraped off with a cotton swab. The cells that
migrated through the membrane pores, which were attracted by
the FBS, were fixed in 100% methanol and stained with 0.1%
toluidine blue solution for 2 minutes. The migrated cells were
digitally photographed under 200X magnification using a light
microscope (NikonTM). The experiments were performed in
triplicate, and 5 random fields were photographed and subjected
to cell counting using the ImageJH free software. The migration
index was calculated as the mean 6 SD of cells counted per-field,
and control cells were compared to finasteride-treated cells.
Human skin fibroblasts (WS1– ATCC) were employed as positive
controls and were exposed to the same assay conditions as the
prostate cells.
Wound Healing Assay
Cell migration was further investigated using a different
migration assay for the PC3 and DU145 cell lines, which were
cultivated in 6-well plates at 46104 cells/cm2 until 100%
confluence was achieved. The monolayers were wounded
(scratched) in a straight line across the well with a 200 ml pipette
tip using a sterile, 6-well culture plate lid as a ruler, to obtain a
regular scratch. The wounded monolayers were then washed twice
with D-PBS (GIBCO/InvitrogenTM) to remove cell debris.
Culture medium with or without 50 mM of finasteride was added
to the control and treatment wells. The wound area was
subsequently inspected after 24, 48, 72 and 96 hours using an
inverted phase contrast microscope with digital camera. The
wound healing speed was calculated as the percentage of the initial
wound until total wound closure at the different time-points using
the ImageJH free software.
Matrigel Invasion Assay
The invasive potentials of all four cell lines were investigated
using BD BioCoatTM MatrigelTM Invasion Inserts (BD Bioscien-
cesTM). The matrigel-coated porous membrane (8 mm pore size)
was hydrated with 500 ml of serum-free bicarbonate-based
medium for 2 hours. After hydration, 500 ml of RPMI 1640
medium with 5% FBS (for LNCaP, PC3 and DU145 cells) or
500 ml of keratinocyte medium with 5% FBS (for RWPE-1 cells)
was added to the lower chamber of the 24-well plate. These
prostate cell lines were previously cultivated in 50 mM finasteride
medium or control medium for 72 hours, harvested and
individually cultivated in 200 ml of serum-free medium (with or
without 50 mM finasteride) in the insert at a density of 16105 total
cells. The plates were incubated in an incubator with 5% CO2 at
37uC for 22 hours, according to the manufacturer’s guidelines.
The uninvaded cells on the top of the insert membrane were
scraped off with a cotton swab. The cells that invaded the Matrigel
matrix and migrated to the opposite side of the membrane, which
were attracted by the FBS, were fixed in 100% methanol and
stained with 0.1% toluidine blue solution for 2 minutes. The
invaded cells were digitally photographed under 200X magnifica-
tion using a light microscope (NikonTM). The experiments were
performed in triplicate, and 5 random fields were photographed
and subjected to cell counting using the ImageJH free software.
The invasion index was calculated as the mean 6 SD of cells
counted per-field, and control cells were compared to finasteride-
treated cells.
Western Blotting
The remaining cell extracts were used to determine AR
expression levels. This determination was performed due to the
discrepant literature on the expression of these receptors by these
cell lines. Briefly, a protein sample (70 mg) that had been
previously quantified using the NanoDrop 2000 (Thermo
ScientificTM) spectrophotometer was loaded onto a 10% SDS-
PAGE gel under reducing conditions. The proteins were
transferred onto a nitrocellulose membrane (Sigma CoTM), which
was subsequently blocked with 5% bovine serum albumin (BSA) in
10 mM Tris–HCl (pH 7.5), 150 mM NaCl and 0.1% Tween-20
(TBS-T) for 1 hour. The membranes were then incubated at 4uC
overnight with the AR (GenetexTM) antibody. The membranes
were washed 5 times for 5 minutes in TBS-T and incubated for 2
hours at room temperature with the proper, peroxidase-conjugat-
ed secondary antibodies (ABCAMTM). After washing in TBS-T,
the membranes were visualized using 3,39-diaminobenzidine and
photographed.
Statistical Analysis
The obtained data were analyzed using the INSTATTM
software using the two-tailed Student’s T test (P,0.05) to compare
the different treatments and their respective controls (viability,
migration, invasion), or using ANOVA and Dunnet’s post hoc test
(MMPs and TIMPs assays).
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Results
Finasteride Exposure and Cell Viability
Cell viability was not significantly affected by either of the
finasteride doses that were employed in the present investigation.
Cells did not present aspects of cell death or loss of viability, even
after 72 hours of 50 mM finasteride exposure (Figure S1).
MMP2 and MMP9 Activity Assays
In control conditions, it was observed that PC3 cells secreted
twice as much MMP2 and MMP9 into their CM as RWPE-1 cells
(IOD values – data not shown). LNCaP cells did not secrete
detectable levels of MMP2 or MMP9 into their CM (IOD values
data – not shown). However, DU145 cells secreted high quantities
of MMP2 and MMP9 (Figure 1a). For the cell extracts, no cell line
presented detectable MMP2 or MMP9 activities, demonstrating
that these cell lines do not hold MMPs at their membrane (data
not shown).
Upon finasteride exposure, it was observed that, for RWPE-1
cells at the employed low dose (10 mM), 72 hours of exposure was
sufficient to induce significant downregulation of both the activity
of both MMPs in the CM (Figure 2a); these values were reduced
by 25% and 30% for MMP2 and MMP9, respectively, relative to
the control values. On the other hand, for the employed finasteride
high dose (50 mM), the MMP2 and MMP9 activities were
significantly downregulated at all time points that were tested,
up to 90% and 55% after 72 hours of exposure, respectively
(Figure 2a).
In the PC3 cell line, low-dose finasteride exposure induced the
significant downregulation of MMP2 and MMP9 activities at only
the 24 hour time point (Figure 3a). On the other hand, high-dose
finasteride significantly induced the downregulation of MMP2 at
the 48 hour and 72 hour time points and of MMP9 at all time
points that were assessed, with up to a 70% reduction (Figure 3a).
Given that the results from the other cell lines showed that only
the high-dose finasteride exerted effects on MMP activity, only the
high dose at 72 hour was investigated for the DU145 cell line. For
the DU145 cell line, high-dose finasteride induced a significant
downregulation of MMP2 activities of approximately 43%
(Figure 1b) (p,0.01). However, the MMP9 activities were not
significantly modulated by finasteride exposure (Figure 1b).
TIMP-1 and TIMP-2 Protein Quantification
When the cell lines were cultivated without finasteride, PC3
cells produced two times more TIMP-1 than the RWPE-1 cells;
however, the amount of TIMP-2 was the same (IOD values).
LNCaP cells produced low levels of TIMP-1 and TIMP-2 that
neared the lower detection limit of the assay (IOD values). DU145
cells produced high quantities of TIMP-1 (IOD values – data not
shown).
Upon finasteride exposure of the tested RWPE-1 cell line, both
doses significantly induced upregulation of TIMP-2 expression at
the 72 hour time point, which was up to 150% more expression
than the control treatment (Figure 2b). As for PC3 cells, TIMP-1
and TIMP-2 expression showed no significant modulation, except
for the 10 mM finasteride dose at 24 hours of exposure (Figure 3b).
Finasteride did not induce any significant changes in the
expression of TIMP-1 or TIMP-2 in LNCaP or DU145 cell lines
(data not shown).
Figure 1. Finasteride’s effects on MMP2 and MMP9 activities in the conditioned medium of DU145 cells. a) Conditioned medium (CM)
of untreated (Control) and finasteride-treated DU145 cells was collected, concentrated and analyzed for MMP2 and MMP9 activities using a gelatin
zymography assay. (S) Standards, (P) Tissue extract of a gastric ulcer that was used as a positive control. These cells secreted high quantities of MMP2
and MMP9 into their CM, as shown by the bright bands on the dark background. b) High-dose finasteride (50 mM) downregulated MMP2 activity up
to 43% after 72 hours of exposure, as quantified using the ImageJTM software. Data are expressed as a fold-change graphic of the IOD values that
were obtained from the bands in the (a) figure for finasteride-treated cells over control cells. (**) Statistically significant values with p,0.01.
Experiments were carried out in triplicate.
doi:10.1371/journal.pone.0084757.g001
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Migration Assay
In regular culture medium, the tested cell lines exhibited
different migration potentials. RWPE-1 cells migrated more (mean
of 32 cells/field) than PC3 cells (mean of 24 cells/field), which, in
turn, migrated more than LNCaP cells (mean of 8 cells/field).
DU145 was the most migrating cell line investigated (mean of 85
cells/field) (Figure 4). After 72 hours of finasteride exposure
(50 mM), migration was inhibited significantly in RWPE-1 cells
(p,0.01) and LNCaP cells (p,0.05). PC3 and DU145 cell
migration was slightly inhibited; however, the inhibition was not
significant (p.0.05) (Figure 4). Human WS1 fibroblasts (positive
control) migrated promptly through the membranes (Figure 4).
Wound Healing Assay
To confirm that the PC3 and DU145 cell line migration
potentials were not influenced by finasteride exposure, a different
migration assay was performed for these cell lines. After the wound
area was inflicted upon the monolayers, it was possible to observe
that, for both cell lines, finasteride slightly inhibited cell migration
(Figure 5a and 5c); however, this difference was not significant
(Figure 5b and 5d), which confirmed the results that were obtained
from the previous migration insert assay (Figure 4).
Figure 2. Finasteride’s effects on MMP2 and MMP9 activity and TIMP-1 and TIMP-2 expression in the conditioned medium of
RWPE-1 cells. a) Conditioned medium of untreated (Control) and finasteride-treated RWPE-1 cells were collected, concentrated and analyzed for
MMP2 and MMP9 activities using their respective BiotrakH Activity Assays. Low-dose finasteride (10 mM) for 72 hours of exposure downregulated
MMP2 and MMP9 activity by 25% and 30%, respectively, when compared to control values. High-dose finasteride (50 mM) downregulated MMP2 and
MMP9 activities at all tested time points, up to 90% and 55% after 72 hours of exposure, respectively. b) Conditioned medium of untreated (Control)
and finasteride-treated RWPE-1 cells were collected, concentrated and analyzed for TIMP-1 and TIMP-2 protein expression using their respective
BiotrakH Assays. Finasteride exposure, at both doses, induced the upregulation of TIMP-2 expression at the 72 hour time point, up to 150% more
expression than control levels. Data are expressed as a fold-change graphic of the IOD values that were obtained for finasteride-treated cells over
those of the control cells. (*) Statistically significant values with p,0.05.
doi:10.1371/journal.pone.0084757.g002
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Matrigel Invasion Assay
In regular culture medium, the cell lines exhibited different
invasion potentials. DU145 and PC3 cells were the most invasive
cell lines, with a means of 97 cells/field and 75 cells/field,
respectively (Figure 6). The LNCaP cell line, which was also
tumoral, curiously exhibited a low invasive potential, with a mean
of 5 cells/field (Figure 6). The non-tumoral cell line RWPE-1 also
exhibited low invasive potential, as expected, with a mean of 9
cells/field (Figure 6).
Finasteride inhibited cell invasion in all of the tested cell lines.
DU145 and PC3 cell invasion was significantly reduced (p,0.001)
followed by RWPE-1 (p,0.01) and LNCaP (p,0.05) (Figure 6).
Western Blotting
AR was detected in the extracts of the LNCaP and RWPE-1 cell
lines, as expected. However, PC3 cells, which are considered to be
AR2, presented high expression of this receptor under our
experimental conditions. DU145 cells did not express AR
(Figure 7).
Discussion
In this study, we evaluated the effects of different doses of
finasteride on the prostate cells lines RWPE-1, LNCaP, PC3 and
DU145 for different periods of exposure. Initially, we demonstrat-
ed that finasteride did not induce substantial cell death in any of
Figure 3. Finasteride’s effects on MMP2 and MMP9 activity and TIMP-1 and TIMP-2 expression in the conditioned medium of PC3
cells. a) Conditioned medium of untreated and finasteride-treated PC3 cells was collected, concentrated and analyzed for MMP2 and MMP9 activities
using their respective BiotrakH Activity Assays. Low-dose finasteride exposure (10 mM) did not induce the downregulation of MMP2 or MMP9
activities, except at the 24 hour time point. High-dose finasteride induced the downregulation of MMP2 at the 48 hour and 72 hour time points and
of MMP9 at all assessed time points, up to 70% reduction. b) Conditioned medium of untreated (Control) and finasteride-treated PC3 cells was
collected, concentrated and analyzed for TIMP-1 and TIMP-2 protein expression using their respective BiotrakH Assays. Finasteride exposure did not
induce any significant modulation of TIMP-1 and TIMP-2 expression, except for the 10 mM finasteride dose at 24 hours of exposure. Data are
expressed as a fold-change of the IOD values obtained for finasteride treated cells over control cells. (*) Statistically significant values with p,0.05.
doi:10.1371/journal.pone.0084757.g003
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the tested lines under any of the experimental conditions or
techniques that were employed. Although it was previously
reported that finasteride induced apoptosis in LNCaP cells
[17,18], the MTT technique, which was employed in both papers,
is merely a proliferation assay. Although this method is suitable for
anti-proliferative drug screening [19], it can lead to misleading
data when employed as a viability assay without the proper backup
assays. This was highlighted in some reports, in which the authors
[4] first claimed that finasteride reduced the viability of LNCaP
cells (using the MTT assay) and immediately claimed it reduced
RWPE-1 cell growth (using the same MTT assay), which is an
entirely different parameter. Therefore, although it is a very basic
technique, trypan blue staining is more suitable for viability
assessment because non-viable cells allow the dye to enter their
membranes [20]. Moreover, published reports indicate that
finasteride does not alter the expression profile of important
proteins that are commonly used as apoptotic markers, such as
caspase-3, insulin growth factor-1, Bcl-2, p53 and p21, and that its
exposure leads to the downregulation of other apoptotic factors,
such as caspase-7 and IGFBP-3, in prostate cancer samples from
patients undergoing radical prostatectomy [21]. More evidence
suggesting that finasteride might not always induce cell death was
provided by Sawaya et al., (2002), who showed that its exposure
decreased the levels of caspase that were detected in alopecia-
treated patients when compared to non-affected individuals [22].
In subsequent experiments, we demonstrated that these cell
lines produced low levels of MMPs in conditioned medium, even
when more sensitive methods were used, such as those employed
as a comparison to regular gelatin zymography. We also
demonstrated that this activity was restricted in the CM because
none of the tested cell lines exhibited MMP2 or MMP9 activities
in their cell extracts. Interestingly, the obtained IODs from the
control CMs did not correspond to the tumoral grading of these
cell lines: although the most aggressive cell line, PC3, had greater
MMP activity, the non-tumoral cell line, RWPE-1, had greater
MMP activities than the tumoral cell line LNCaP. Additionally,
we demonstrated that the DU145 cell line secretes more MMP2
and MMP9 than the other two tumoral cell lines that were
investigated. It is important to note the variability in literature data
about the levels, activity and gene expression of these metallo-
peptidases in these cell lines. Some authors have reported
detectable gene expression of MMP7, MMP16, TIMP-1 and
TIMP-2 in LNCaP and PC3 cells but no gene expression of
MMP2 [23]. Other authors have reported that PC3 cells highly
express MMP14 and MMP16, while LNCaP cells express them at
lower levels [24]. On the other hand, MMP15 gene expression was
reported to be higher in LNCaP cells than in PC3 cells [24].
Regarding protein expression, previous authors reported detect-
able levels of MMP1, MMP14, MMP15 and MMP16 by western
blotting analyses in LNCaP and PC3 cells. TIMP-1 and TIMP-2
were detected, but at low levels [24]. On the other hand, low
activities of MMP1, MMP7 and MMP13 were detected using
gelatin zymography assays in the conditioned medium of these cell
lines [24]. Our group has previously reported that when these cell
lines are cultivated in regular culture medium, all display low
activities of MMP2 and MMP9 in their CM [16]. We again
observed these findings in the present report.
Figure 4. Finasteride’s effects on the migration of the human prostate cell lines RWPE-1, LNCaP, PC3 and DU145. The prostate cell
lines were previously cultivated in 50 mM finasteride or control medium for 72 hours and individually cultivated in 200 ml of serum-free medium (with
or without 50 mM finasteride) in the migration insert at a density of 16105 total cells. After 22 hours, cells that migrated through the 8 mm porous
membrane were fixed, stained and counted within five random fields using a light microscope. Experiments were performed in triplicate.
Representative photomicrographs of untreated and finasteride-treated cells are shown on the left side. Human fibroblasts (WS1 cell line) were
employed as migration-positive control cells, and a representative image is shown on the bottom-left side. Scale bar = 40 mm. Finasteride significantly
inhibited the cell migration of the RWPE-1 and LNCaP cell lines but not of the PC3 and DU145 cell lines. Data are expressed as the mean 6 SD of the
migrating cells. (*) Statistically significant values with p,0.05. (**) Statistically significant values with p,0.01.
doi:10.1371/journal.pone.0084757.g004
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However, when the cells were cultured with diluted finasteride,
PC3 and RWPE-1 cells exhibited significantly lower MMP2 and
MMP9 activities in their CM. Furthermore, our results demon-
strated that only high-dose finasteride (50 mM) was able to
downregulate the MMP2 and MMP9 activities in these cell lines,
as previously reported [16]. The activity of MMP2 in DU145 cells
was also significantly inhibited by finasteride, which is a novel
finding.
Interestingly, lower dose of finasteride downregulated MMP
activities at the 24 hour time point in the PC3 cell line. At the 48
and 72 hour time points, the activities were normal, which we
believe may be an adaptive response of the cells to the low-dose
finasteride environment. The consistent downregulation of MMP
activities that were induced by the higher-dose finasteride, through
all experiments supports this hypothesis, as previously formulated
in the normal/adaptive state/toxic state of cells/biological systems
in response to different doses of a given antiandrogen [25]. On the
other hand, RWPE-1 cells exhibited downregulated MMP2 and
MMP9 activities at the 72 hour time point for the lower finasteride
dose, indicating that this cell line has a limited ability to adapt
compared to the PC3 cell line.
Based on these observations, it was expected that the expression
of TIMP-1 and TIMP-2 could be modulated by finasteride
because the activities of MMPs were regulated in this manner. We
then proceeded to quantify the amounts of TIMP-1 and TIMP-2
in the CM of these cells under control and finasteride-treated
conditions. Again, the LNCaP cell line did not express significant
TIMP-1 or TIMP-2 in their CM. The expression of TIMP-1 was
higher in PC3 cells than in RWPE-1 cells and similar to that in
DU145 cells; however, the expression of TIMP-2 was similar in
Figure 5. Finasteride’s effects on the migration of the human prostate cell lines PC3 and DU145 in the wound closure migration
assay. Cells were cultivated in 6-well plates at 46104 cells/cm2 until 100% confluence was achieved. The monolayers were scratched in a straight line,
and the wounded monolayers were then given culture medium with or without 50 mM finasteride. The wound area was inspected after 24, 48, 72 and
96 hours using an inverted phase contrast microscope with a digital camera. a) Representative images showing the wound closure of finasteride-
treated and control PC3 cells at 0 to 72 hours. Red highlighted areas represent the open-wound area. Scale bar = 50 mm. b) The initial red highlighted
areas were measured using the ImageJTM software, and the remaining areas were calculated as a percentage of the initial wound area. A wound-
closure graphic was made by dividing the area values that were obtained at the indicated time points for the control and finasteride-treated cells.
Finasteride slightly inhibited cell migration; however, this difference was not statistically significant (p.0.05). c) Representative images showing the
wound closure of finasteride-treated and control DU145 cells at 0 to 72 hours. Red highlighted areas represent the open wound area. Scale
bar = 50 mm. d) As observed for the PC3 cells, finasteride slightly inhibited cell migration (p.0.05).
doi:10.1371/journal.pone.0084757.g005
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the CMs of both cell lines and control-treated cells. Although
finasteride (50 mM) induced the downregulation of MMP activity
in PC3, DU145 and RWPE-1 cells, this modulation might occur
via different mechanisms in the cells, such as the upregulation of
TIMP-1 and TIMP-2 in RWPE-1 cells or the reduced expression
of MMPs by PC3 and DU145 cells. While these findings are
relevant, one question is still unanswered: could finasteride induce
high-grade prostate cancer? Therefore, the next experiment aimed
to verify if this drug could directly modulate cell migration and
invasion, which are important features related to tumor metastasis
and, consequently, high-grade prostate cancer cases [26,27].
Finasteride, when employed at a high dose, inhibited cell
migration in the RWPE-1 and LNCaP cell lines but not in the
PC3 and DU145 cell lines, in both migration assays. Interestingly,
we found that RWPE-1 cells, which are classically defined as non-
tumoral, had higher migration potential that the tumoral LNCaP
cell line (compare RWPE-1 control cells to LNCaP control cells),
which showed that this cell line did not display all of the
characteristics that most authors would consider normal for this
prostate cell line, given that tumoral cells should display high
migration and invasion capabilities. In fact, previous authors have
reported surprising results with this cell line, such as undetectable
levels of nuclear AR, cytosolic SRD5A1, and nuclear SRD5A2
proteins using western blotting techniques [4]. Although cell
motility is an important feature for the success of cells to
metastasize, cell invasion is mandatory for tumor cells to migrate
through the ECM [10,12,16] to gain access to blood or lymph
vessels and ultimately reach circulation. We exposed all cell lines to
50 mM finasteride for 72 hours and then subjected them to
another 22 hours of finasteride exposure during the transwell-
MatrigelTM invasion assay. Initially, we again observed surprising
results for RWPE-1 cells, such as the ability of cell invasion. This
Figure 6. Finasteride’s effects on the invasion of the human prostate cell lines RWPE-1, LNCaP, PC3 and DU145. The prostate cell lines
were previously cultivated in 50 mM finasteride or control medium for 72 hours and individually cultivated in 200 ml of serum-free medium (with or
without 50 mM finasteride) in the MatrigelH invasion insert at a density of 16105 total cells. After 22 hours, cells that invaded through the matrigel
matrix and porous membrane were fixed, stained and counted within five random fields using a light microscope. Experiments were performed in
triplicate. Representative images of untreated and finasteride-treated cells are shown on the left side. Scale bar = 40 mm. Finasteride significantly
inhibited the cell invasion of all tested cell lines. Data are expressed as the mean 6 SD of the invading cells. (*) Statistically significant values, with
p,0.05. (**) Statistically significant values, with p,0.01. (***) Statistically significant values, with p,0.001.
doi:10.1371/journal.pone.0084757.g006
Figure 7. Western blots of whole protein extracts from RWPE-1, LNCaP, PC3 and DU145 cell lines. The prostate cell lines were cultivated
in regular medium until 100% confluence and individually processed for protein extraction. After electrophoresis, the proteins were transferred onto
a nitrocellulose membrane and probed with an anti-androgen receptor (AR) antibody. After incubation with the secondary antibody, the bands were
visualized with DAB. All cell lines employed in this investigation expressed AR except for the DU145 cell line. Experiments were carried out in
triplicate. (MW) Molecular Weight Standard. The estimated MW of AR is approximately 110 kDa.
doi:10.1371/journal.pone.0084757.g007
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finding and the previously described high migration potential of
this cell line support the concern that has been raised regarding
RWPE-1 cell line physiology and non-tumoral status [37]. We
have also demonstrated and observed that untreated LNCaP cells
have approximately one-tenth of the invasion potential of
untreated PC3 cells, as reported previously [27,28], and, more
importantly, our results clearly demonstrate that finasteride
significantly inhibits prostate cancer cell invasion in all four tested
cell lines. Others studies using vascular smooth muscle cells (AR+)
and fibroblasts (AR+) have reported the consistent inhibition of
migration speed by flutamide and bicalutamide, respectively
[29,30]. Although the cells were exposed to finasteride in FBS-
free medium in the present study, these cell lines were able to
synthesize T even in an FBS-starved medium environment by
acquiring complete steroidogenic ability to produce androgens
[31]. Thus, our findings confirm those of previous reports [29–30]
showing that DHT stimulates cells to migrate and invade more
than T, which does not occur on a finasteride-rich microenviron-
ment.
Intriguingly, it is well known and reported that these four cell
lines present different integrities of the androgenic signaling
machinery, mainly in terms of AR mRNA and protein expression
[4,32–37]. Finasteride treatment induced a similar result of
reduced MatrigelTM invasion ability by these cell lines, and
further complicating this issue, our PC3 cells presented strong
bands for AR. Although being classically considered as AR2, some
previous reports have demonstrated that PC3 and DU145 express
this receptor [35]. Even more intriguing, other authors report that
descendent PC3 cell lines, which were originally obtained from the
ATCC supplier, and expanded more than 70 passages from
receipt, had detectable levels of AR mRNA, being classified as
PC3AR+ [36]. We hypothesize that recent reports, which mainly
used over-passaged cell lines, may have failed to observe this
change in AR mRNA expression given that the early classical
studies had already reported this cell line as AR2.
Therefore, although it is accepted that AR may play a role in
the regulation of cell migration and invasiveness [30,38,39],
similar results showing the downregulation of these features after
finasteride exposure in cell lines that express or do not express this
receptor suggest that this effect may be due to a non-canonical
mechanism of action of finasteride in these cells, which remains to
be elucidated.
Conclusion
Although the debate regarding the higher incidence of high-
grade prostate cancer among 5-ARI-treated patients remains, our
findings indicate that finasteride may attenuate tumor aggressive-
ness and invasion, which could vary depending on the phenotypes
of the patients’ prostate cells, mainly the cell’s androgen
responsiveness status. Although these results may seem beneficial
for finasteride-treated patients, future studies are necessary to
elucidate the mechanism by which finasteride exerts its effects on
prostate tumoral cells.
Supporting Information
Figure S1 Representative images of human prostate
cells general morphology and cell density (cells/area)
under control conditions, and after 72 h of finasteride
exposure (50 mM). Prostate cell lines RWPE-1, LNCaP, PC3,
and DU-145 were plated at 26104cels/cm2, cultivated until
reaching 60% confluence, and exposed to finasteride. General
morphology was similar between untreated and finasteride-treated
cells. No significant apoptotic or necrotic morphological char-
acterists were observed. Scale bar = 100 mm.
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